Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

State University of New York at Buffalo: Clinical Trials & FDA Approval Profile

State University of New York at Buffalo (Global / Institutional) sponsors 18 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 8 active protocols (6 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)27.8%
Median Closed Enrollment vs National (145 pts)60 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for State University of New York at Buffalo
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)18
Active Pipeline (Recruiting Now)8 (6)
Completed vs Stopped Early5 / 5 (27.8%)
Median Closed Actual Enrollment60 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the State University of New York at Buffalo Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI